The motivation and process for developing a consortium-wide time and motion study to estimate resource implications of innovations in the use of genome sequencing to inform patient care.

Autor: Hoban HG; Institute for Human Genetics, University of California, San Francisco, California, USA., Yip TA; Institute for Human Genetics, University of California, San Francisco, California, USA., Chau JC; Division of Genomic Medicine, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA., Bensen JT; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Desrosiers LR; Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA., Finnila CR; HudsonAlpha Institute for Biotechnology, Huntsville, Alabama, USA., Hindorff LA; Division of Genomic Medicine, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA., Kelly NR; Division of Pediatric Genetic Medicine, Department of Pediatrics, Children's Hospital at Montefiore and the Albert Einstein College of Medicine, Bronx, New York, USA., Lynch FL; Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon, USA., Rolf BA; Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, Washington, USA., Smith HS; Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, Texas, USA., Wasserstein MP; Division of Pediatric Genetic Medicine, Department of Pediatrics, Children's Hospital at Montefiore and the Albert Einstein College of Medicine, Bronx, New York, USA., Hassmiller Lich K; Department of Health Policy and Management, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Jazyk: angličtina
Zdroj: Clinical and translational science [Clin Transl Sci] 2024 Jan; Vol. 17 (1), pp. e13635. Date of Electronic Publication: 2023 Dec 08.
DOI: 10.1111/cts.13635
Abstrakt: Costs of implementing genomic testing innovations extend beyond the cost of sequencing, affecting personnel and infrastructure for which little data are available. We developed a time and motion (T&M) study within the Clinical Sequencing Evidence-Generating Research (CSER) consortium to address this gap, and herein describe challenges of conducting T&M studies within a research consortium and the approaches we developed to overcome them. CSER investigators created a subgroup to carry out the T&M study (authors). We describe logistical and administrative challenges associated with resource use data collection across heterogeneous projects conducted in real-world clinical settings, and our solutions for completing this study and harmonizing data across projects. We delineate processes for feasible data collection on workflow, personnel, and resources required to deliver genetic testing innovations in each CSER project. A critical early step involved developing detailed project-specific process flow diagrams of innovation implementation in projects' clinical settings. Analyzing diagrams across sites, we identified common process-step themes, used to organize project-specific data collection and cross-project analysis. Given the heterogeneity of innovations, study design, and workflows, which affect resources required to deliver genetic testing innovations, flexibility was necessary to harmonize data collection. Despite its challenges, this heterogeneity provides rich insights about variation in clinical processes and resource implications for implementing genetic testing innovations.
(© 2023 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje